A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. Read More ›
Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM. Read More ›
Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment. Read More ›
Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone. Read More ›
Data from the IMAGE study support real-world use of isatuximab in patients with relapsed/refractory multiple myeloma, with findings similar to those reported for ICARIA-MM. Read More ›
Patient-reported outcomes with ciltacabtagene autoleucel are consistent with clinical findings and support its use in heavily pretreated patients with relapsed/refractory multiple myeloma. Read More ›
Iberdomide, a novel cereblon E3 ligase modulator, in combination with dexamethasone showed encouraging results in a multicohort, open-label, phase 1/2 trial. Read More ›
Iberdomide and mezigdomide have shown to be more potent than traditional immunomodulators and may have potential as new oral agents in multiple myeloma. Read More ›
Recent initiative to boost new technologies in oncology focuses on the impact of blood testing as a major area of interest in better understanding multiple myeloma. Read More ›
